You are here

Press Releases

DUBLIN — February 20, 2018 — Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2018, which ended January 26, 2018.

SANTA CLARA, Calif.—February 20, 2018—Cardiva Medical®, an innovator in the field of vascular closure, today announced that the company has closed on $11 million in additional financing — bringing total equity and debt financing in the current round to $41 million.

DUBLIN and VIENNA — February 15, 2018 — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that new data from its at-home pediatric study of the MiniMed(TM) 670G system in patients 7-13 years of age were presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria. 

PETAH TIKVA, Israel, February 15, 2018 — DreaMed Diabetes, developer of diabetes management solutions, announced today that it received CE Mark for the Advisor Pro decision-support platform for assisting healthcare professionals in the management of Type 1 diabetes.

REDWOOD CITY, Calif.—HeartFlow, Inc. today announced the closing of its Series E financing, securing $240 million. The company will use the proceeds from this financing to ramp up commercial expansion of the HeartFlow® FFRct Analysis, continued technology innovation and additional clinical studies.

DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the launch of a new indication and Women's Initiative focused on heart recovery education and awareness.

Tokyo-based Terumo Corporation has today announced an investment of £33 million in one of its subsidiary companies, Vascutek Limited, located near Glasgow.

Hundreds of hospitals across the United States will have access to tools and resources to help improve care and lower readmission rates for myocardial infarction (MI) patients as part of the American College of Cardiology’s expanded Patient Navigator Program: Focus MI Quality Campaign.

COPENHAGEN, February 8, 2018 — Acesion Pharma ("Acesion" or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects will be conducted at the Centre for Human Drug Research (CHDR) in the Netherlands and is due to start in March 2018.

Pittsburgh, PA, February 7, 2018 —, the new Website and mobile app that give you instant access to data doctors report from almost one million doctors’ offices across the nation, has released its current list of the nation’s 14 Influenza hot spots (by metro area) in the country.

KFAR MALAL, Israel, Feb. 5, 2018 — Medial EarlySign, a leader of machine-learning based solutions to improve non-communicable disease management, today announced the results of an additional clinical data study in the domain of diabetes — identifying diabetic patients who are at highest risk for having renal dysfunction within one year.

DUBLIN and LEIPZIG — January 30, 2018 — Medtronic plc (NYSE: MDT) today added to its robust body of clinical evidence supporting the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) with new presentations that demonstrated durable and consistent clinical outcomes in peripheral artery disease (PAD).

DUBLIN — January 26, 2018 — Medtronic plc (NYSE: MDT) today announced the initiation of its investigational device exemption (IDE) study for the Abre(TM) venous self-expanding stent system. The ABRE IDE Study will evaluate the safety and effectiveness of the Abre stent in subjects with iliofemoral venous outflow obstruction.

DUBLIN — January 24, 2018 — Medtronic plc (NYSE: MDT) today announced the launch of the ENCHANT (ENdurantCHEVAR New Indication Trial) study. The post-market, non-interventional, multi-center, non-randomized, single-arm study will enroll approximately 150 patients across 25 sites in Europe and Russia, and will evaluate the safety and performance of a ChEVAR procedure using the Endurant(TM) II/IIs stent graft system in a real-world setting.

NEW YORK, Jan. 22, 2018 — Noted cardiologists, Jennifer H. Mieres, MD, and Stacey E. Rosen, MD, launch Heart Smart For Women; Six S.T.E.P.S. in Six Weeks To Heart- Healthy Living; a new book that demystifies the science, biology and statistics surrounding heart disease while providing a user-friendly program for successful heart-healthy living.

Baxter International Inc. (NYSE: BAX), a global leader in sterile medication production and delivery, today announced the U.S. Food and Drug Administration (FDA) approval of Bivalirudin in 0.9 percent Sodium Chloride Injection (bivalirudin). Bivalirudin is a specific and direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI).

TITUSVILLE, N.J., Jan. 16, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced findings from the U.S. Food and Drug Administration's (FDA) Mini-Sentinel assessment, confirming the positive safety and efficacy profile of XARELTO® (rivaroxaban) established in the phase III ROCKET AF clinical trials, were published in Pharmacoepidemiology & Drug Safety.

International Biophysics Corporation, a global medical device manufacturer based in Austin, Texas, announced they have received FDA 510k clearance for their FloPump 32 centrifugal disposable heart pump.

DUBLIN — January 16, 2018 — Medtronic plc (NYSE:MDT) today announced that the company's Neurovascular business unit received U.S. Food and Drug Administration (FDA) clearance of the Riptide(TM) Aspiration System, adding a valuable tool to the Acute Ischemic Stroke (AIS) product portfolio.

Kirk N. Garratt, M.Sc, M.D, has been appointed medical director of Christiana Care Health System’s Center for Heart & Vascular Health. Dr. Garratt succeeds Tim Gardner, M.D., who retired after 12 years of dedication to Christiana Care and the Delaware community.